Company Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) Drops by -11.42%

Adamas Pharmaceuticals (NASDAQ:ADMS) has tumbled 11.42% during the past week and has dropped 15.34% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 12.61%. Adamas Pharmaceuticals (NASDAQ:ADMS) has underperformed the index by 20.78% in the last 4 weeks. Investors should watch out for further signals and trade with caution. The stock has recorded a 20-day Moving Average of 8.36% and the 50-Day Moving Average is 25.44%.

Adamas Pharmaceuticals (NASDAQ:ADMS) rose 1.77% or 0.22 points on Friday and made its way into the gainers of the day. After trading began at $12.51 the stock was seen hitting $12.765 as a peak level and $12.07 as the lowest level. The stock ended up at $12.64. The daily volume was measured at 487,271 shares. The 52-week high of the share price is $31.84 and the 52-week low is $12.02. The company has a market cap of $271 million. The company shares have dropped 28.79% in the past 52 Weeks. On December 28, 2015 The shares registered one year high of $31.84 and one year low was seen on February 25, 2016 at $12.02. The 50-day moving average is $14.33 and the 200 day moving average is recorded at $17.34. S&P 500 has rallied 2.61% during the last 52-weeks.

Investors should note that the Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged that Lieberburg Ivan M, director of Adamas Pharmaceuticals Inc, had unloaded 3,000 shares at an average price of $16.23 in a transaction dated on December 7, 2015. The total value of the transaction was worth $48,690. Currently the company Insiders own 39.87% of Adamas Pharmaceuticals shares according to the proxy statements. Institutional Investors own 52.23% of Adamas Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -15.79%.

Many analysts have stated their opinion on the company shares. Mizuho Securities initiates coverage on Adamas Pharmaceuticals (NASDAQ:ADMS). Mizuho Securities has a Neutral rating on the shares. As per the latest report, the brokerage house announces the price target to $26 per share. The rating by the firm was issued on January 19, 2016.

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on development and commercialization of therapeutics targeting chronic disorders of central nervous systems (CNS). It is engaged in modifying pharmacokinetic (PK) profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. It develops its lead product, ADS-5102 (amantadine hydrochloride), for a complication associated with treatment of Parkinsons disease known as levodopa induced dyskinesia, and as a treatment for one or more additional CNS indications. Its other product candidate is ADS-8704. Through a partnership with Forest Laboratories Holdings Limited, its portfolio includes two drugs commercially available in the United States: Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release capsules.

Source: EtH

Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

Do we disclose any information to outside parties?

We do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.

What information do we collect?

We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.

When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.

What do we use your information for?

When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.

We send periodic emails

The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.

How do we protect your information?

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.

Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.

Online Privacy Policy Only

This online privacy policy applies to information collected through our website and social media platforms.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may reply to this email.

DISCLAIMER

This website/newsletter is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.